JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Shafie S. Fazel
Richard D. Weisel
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fazel, S. S.
Right arrow Articles by Li, R.-K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fazel, S. S.
Right arrow Articles by Li, R.-K.
Related Collections
Right arrow Cardiac - other

J Thorac Cardiovasc Surg 2008;136:1388-1389
© 2008 The American Association for Thoracic Surgery

Brief Communication

Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential

Shafie S. Fazel, MD, PhD, Denis Angoulvant, MD, MSc, Jagdish Butany, MD, Richard D. Weisel, MD, Ren-Ke Li, MD, PhD*

Division of Cardiac Surgery, Department of Surgery, and Department of Pathology, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada

Received for publication November 3, 2007; accepted for publication November 30, 2007.

* Address for reprints: Ren-Ke Li, MD, PhD, Room 3-702, Toronto Medical Discovery Tower, Toronto General Hospital, 101 College St, Toronto, ON, Canada, M5G 1L7. (Email: renkeli@uhnres.utoronto.ca).

The first 20% of the full text of this article appears below.

Cardiac stem cell therapy has received significant attention as a potential biointervention to ameliorate post–myocardial infarction congestive heart failure. Recent prospective randomized clinical trials have provided some evidence showing potential efficacy, although the benefit obtained has been relatively small.1Go Thus far, the majority of the evidence suggests that adult stem cells do not cause de novo cardiomyogenesis on a large and reproducible extent. Some have proposed that using embryonic stem cells, which clearly have cardiomyogenic potential, could enhance the beneficial impact of stem cell therapy. Indeed, this may be the case. However, undifferentiated embryonic stem cells are plagued with the potential for teratoma formation.2Go To date, this concern has not been an issue for adult-derived stem cells.

We3Go recently described the substantial functional benefit of transplanting genetically engineered adult-derived mesenchymal stem cells (MSCs) overproducing stem cell factor (SCF) when transplanted immediately after myocardial infarction. Pressure–volume loop analysis during inferior vena caval occlusion showed a 1.9-fold increase (P < 0.001) in the slope of preload-recruitable stroke work in animals that received MSCs . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 BrainHome page
G. Martino, M. Bacigaluppi, and L. Peruzzotti-Jametti
Therapeutic stem cell plasticity orchestrates tissue plasticity
Brain, June 1, 2011; 134(6): 1585 - 1587.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The American Association for Thoracic Surgery.